CNS drug development and co-marketing agreement, announced by Squibb May 2, expands relationship between the firms beyond insulin to central nervous system disease therapies for depression, anxiety and psychosis. The deal was signed in first quarter and announced by Squibb at its annual meeting. In depression area, Novo-Nordisk has been working on dopamine reuptake inhibitors. GBR-12909 is currently in Phase II clinicals in Europe. Other CNS compounds are: FD- 10571, a non-benzodiazapine anxiolytic; FG-8119, a partial benzodiazapine receptor agonist; and fexometine,a 5-HT reuptake inhibitor with antidepressant properties.
You may also be interested in...
The US agency has announced another month of webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.